Ki Sueng Choi
Associate Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Obsessive–compulsive disorder (OCD) manifests with diverse symptom constellations that likely arise from dysfunction in partially distinct neural circuits. Deep brain stimulation (DBS), paired with high-resolution connectomics, offers a unique window into these pathways in humans. Here, we analyzed clinical outcomes and stimulation sites from 77 treatment-refractory patients with OCD and 39 with Tourette’s syndrome (TS) exhibiting comorbid obsessive–compulsive behaviors (244 electrodes across 15 cohorts and eight targets). Engagement of the previously defined OCD response tract predicted global obsessive-compulsive symptom improvement across heterogeneous targets and diagnoses, spanning both OCD and TS. Beyond broad symptoms, obsessions, compulsions, anxiety, and depression mapped onto distinct yet overlapping subcircuits fragmenting the anterior limb of the internal capsule along a dorsoventral axis. This fine-scale architecture of OCD circuit dysfunction was reproducible across cross-validation schemes and patient subsets. Exploratory analyses identified additional subcircuits for cognitive control and flexibility. Global functional recovery was better explained by combined engagement of multiple symptom-specific rather than a single tract. Collectively, these findings illustrate how invasive neuromodulation can delineate a multi-symptom circuit taxonomy of compulsivity that may guide personalized neuromodulation.
Year:
2025
Recent advances in deep brain stimulation (DBS) of the subcallosal cingulate (SCC) show promise in mitigating the symptoms of treatment-resistant depression (TRD) in humans 1–3 . Monoamines, such as dopamine and serotonin, mediate the effects of pharmacological treatments of depression. However, their roles in recovery following DBS remain elusive, largely due to technical limitations of measuring these neurotransmitters in the living human brain. Here, by leveraging machine learning-enhanced electrochemistry 4–7 , we show that dopamine and serotonin signaling following DBS to the SCC predicted later depressive symptom relief in humans with TRD. We found that both dopamine and serotonin levels increased following subtherapeutic intraoperative SCC stimulation, with each neurotransmitter showing selective responses to distinct decision-making tasks. Furthermore, acute dopamine increases predicted later mood improvements during a social decision-making task, while serotonin enhancement predicted faster responses during a non-social learning task longitudinally. Critically, changes in dopamine and serotonin levels during the social decision-making task jointly predicted depressive symptom remission at 6-month follow-up. These findings illustrate the contribution of both dopamine and serotonin signaling in predicting behavioral improvement and depressive symptom remission in humans with TRD. Such neurochemical plasticity may serve as potential mechanistic biomarkers for SCC DBS mechanism and TRD treatment response. Significance statement Dopamine and serotonin levels increased following acute DBS to the SCC in humans. Acute dopamine and serotonin changes predicted later mood and response speed changes. Sustained TRD recovery was predicted by acute increases in both dopamine and serotonin estimates.
Year:
2025
Deep brain stimulation (DBS) of the subcallosal cingulate cortex (SCC) is a promising intervention for treatment-resistant depression, yet objective biomarkers that track recovery remain limited. This study examined longitudinal changes in stimulation-evoked potentials (SEPs) to characterize how SCC-driven cortical communication evolves during treatment. Ten patients across three SCC-DBS trials underwent high-density EEG recordings at 4 and 24 weeks. SEP features were extracted from source-localized SCC signals and related to clinical outcomes and fractional anisotropy (FA) of midcingulate cingulum. Cortical responses showed a consistent reduction in latency and an increase in magnitude over time, indicating faster and stronger electrocortical signaling with chronic stimulation. Higher baseline midcingulate FA predicted greater latency acceleration, linking SEP timing to white-matter integrity. These findings identify temporal SEP dynamics as candidate mechanistic biomarkers that reflect circuit engagement during SCC-DBS and offer a pathway toward physiology-guided optimization of neuromodulation for depression. Highlights Reduced latency of stimulation evoked potential after 6 months of DBS Larger cortical evoked response to single pulse perturbation after 6 months of DBS Baseline myelin integrity in MCC predicts magnitude of change in EP latency
Year:
2025
Auditory verbal hallucinations (AVH) in treatment-resistant schizophrenia (TR SZ) are often unresponsive to pharmacologic interventions, necessitating novel therapeutic approaches. We report a case of a patient with persistent AVH who underwent deep brain stimulation (DBS) of the substantia nigra pars reticulata (SNr). To investigate the neurophysiological effects of SNr stimulation on cortical activity during AVH, we performed intraoperative electrocorticography (ECoG) over the left inferior parietal cortex using a 63-channel grid. Real-time recordings captured episodes of AVH and revealed elevated theta-gamma phase-amplitude coupling (PAC), a marker of aberrant cortical synchronization. DBS intervention resulted in normalization of PAC dynamics, with both average PAC and spatial distribution returning to non-AVH levels. Clinically, SNr DBS was associated with a 64% reduction in AVH frequency. These findings provide the first real-time functional evidence linking SNr activity to cortical oscillatory changes underlying AVH. This case supports the potential of SNr as a novel neuromodulatory target in TR SZ and highlights theta-gamma PAC as a candidate biomarker for mechanistic tracking of AVH symptomatology.
Year:
2025
Major depressive disorder (MDD) is a leading cause of disability worldwide, yet its diagnosis relies on clinical symptoms alone. Using machine learning applied to deeply phenotyped, medication-free participants with MDD, we identified two neuroanatomical dimensions. Dimension 2 (D2), compared to Dimension 1 (D1), was characterized by reductions in grey and white matter and was associated with limited treatment response to both antidepressant and placebo medications. Validation in UK Biobank general population cohort (n = 37,235) confirmed that D2 is characterized by reduced grey and white matter, alongside widespread cognitive impairments, adverse events in both adulthood and childhood, increased self-harm and suicide attempts, a pro-atherogenic lipid profile, and genetic associations with neurodegenerative traits. These findings suggest that D1 and D2 reflect distinct neurobiological mechanisms underlying MDD, with important implications for and treatment outcomes. External validation was demonstrated in a general population-based cohort that delineated mechanisms underlying heterogeneity in MDD, identifying potential biomarkers that could aid in personalising treatment approaches for this debilitating disorder.
Year:
2025
Therapeutic brain stimulation targets are typically designed to treat specific psychiatric or neurological symptoms. 1–4 This approach presents a dilemma when treating patients with comorbidities, atypical symptom profiles, or overlapping symptoms. Identifying targets that modulate groups of behavioral or cognitive symptoms across diagnoses may provide alternative treatment options and outcomes. Here, we use causal brain mapping and clustering methods to identify two distinct brain networks, based on common patterns of connectivity to lesions that selectively modify behaviors and symptoms. Due to the behavioral items in each cluster, we hypothesize that these networks are related to positive and negative affect, respectively. Across ten different datasets of patients receiving transcranial magnetic stimulation (TMS) or deep brain stimulation (DBS), 1,5,6 stimulation site connectivity to each of our two brain networks independently predicted improvement in depressive symptoms. Thus, we defined two networks which are independently and causally involved in depression symptoms.
Year:
2024
Collaborators (50)
Harith Akram
Consultant neurosurgeon and Honorary Associate Professor
UCL Institute of Neurology, University College London
Vincenzo Fiore
Assistant Professor
Icahn School of Medicine at Mount Sinai
Benicio N. Frey
McMaster University
Joost de Jong
Senior researcher
Maastricht University Medical Centre
Robert Richardson
Director, Functional Neurosurgery
Massachusetts General Hospital
Haochang Shou
Associate Professor
University of Pennsylvania
Ludvic Zrinzo
Professor of Neurosurgery., Head Unit of Functional Neurosurgery
UCL Institute of Neurology, University College London
stephan chabardes
Grenoble Alpes University Hospital
Patricio Riva-Posse
Associate Professor
Emory University
Andrew McIntosh
Professor of Biological Psychiatry
University of Edinburgh
Xiaosi Gu
Associate Professor
University of Texas at Dallas
Catherine Harmer
Associate Head of Department
University of Oxford
Fidel Vila-Rodriguez
Associate Professor
The University of British Columbia
Eileen Joyce
University College London
Sameer Sheth
Baylor College of Medicine
Susan L Rossell
Swinburne University of Technology
David Castle
University of Tasmania
Bryan Strange
Profesor I3
Universidad Politécnica de Madrid
Boadie Dunlop
Professor and Chair
Augusta University Medical College of Georgia
Ignacio Saez
Assistant professor
Icahn School of Medicine at Mount Sinai
Ankur Butala
Associate Professor
Johns Hopkins University School of Medicine
Christopher Butson
Associate Professor
University of Utah
Chao-Gan Yan
Professor
Tsinghua University
Martin Paulus
Laureate Institute for Brain Research
Ayaka Kato
Icahn School of Medicine at Mount Sinai
Martijn Figee
Associate Professor
Icahn School of Medicine at Mount Sinai
Jonathan Savitz
Associate Professor
University of Tulsa
John Deakin
The University of Manchester
Thomas Foltynie
University College London
Alon Mogilner
Associate Professor (Clinical) of Anesthesiology, Perioperative Care and Pain Medicine and Neurosurgery (Academic)
NYU School of Medicine
Rebecca Elliott
The University of Manchester
Andrea A. Kühn
Charité - Universitätsmedizin Berlin
Carsten Finke
Charité - Universitätsmedizin Berlin
Michael Bray
Johns Hopkins University
Irina Strigo
University of California, San Francisco
Christos Ganos
Director
-
Philip Mosley
Commonwealth Scientific and Industrial Research Organisation
Jordan H. Grafman
Professor in Physical Medicine and Rehabilitation, Cognitive Neurology and Alzheimer's Disease Center, Psychiatry and Behavioral Sciences and Weinberg College of Arts and Sciences
Northwestern University Feinberg School of Medicine
Dan Bang
Associate Professor
Aarhus University
Cynthia Fu
University of East London
Michael Okun
Member
Fixel Institute for Neurological Diseases
Heather Whalley
Professor of Neuroscience and Mental Health
University of Edinburgh
Christopher Rozell
Julian T. Hightower Chair
Georgia Institute of Technology
Kara Johnson
Assistant Professor
University of Utah
Kenneth Kishida
Professor
Wake Forest School of Medicine
Madhukar H. Trivedi
Director
University of Texas Southwestern Medical Center
Roland Zahn
King’s College London
Leonardo Barbosa
Research Assistant Professor
Fralin Biomedical Research Institute at VTC
Melanie Ganz
Associate Professor
University of Copenhagen
Beata Godlewska
University of Oxford
Make your next move.
Prepare your application
Review drafts before you send them.